Koninklijke Philips NV vs US Bancorp — how do they compare? Koninklijke Philips NV trades at $24.38 (market cap $23.52B), while US Bancorp trades at $57.07 (market cap $88.86B). The key difference: US Bancorp is far larger — about 3.8× Koninklijke Philips NV's market cap, and Koninklijke Philips NV pays the higher dividend (4.17%). Which is the better fit depends on your goals — on Pluang, investors hold Koninklijke Philips NV for 84 Days and US Bancorp for 97 Days on average.
| PHG | USB | |
|---|---|---|
Market Cap | $23.52B | $88.86B |
Volume | 1,635,069 | 8,869,993 |
Sector | Health | Financials |
52-Week High | $32.91 | $65.42 |
52-Week Low | $23.81 | $45.28 |
Typical Hold Time | 84 Days | 97 Days |
Enterprise Value | $29.87B | $118.35B |
Dividend Yield | 4.17% | 3.79% |
Signals from Pluang's Aura AI — not financial advice
PHG trades at $24.09, down 0.25% on the day, with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with net income turning positive to $895M in 2025 after previous losses, supported by strong operational cash flow of $1.17B. Recent news highlights product innovations including new CT systems and AI healthcare tools, while institutional investors like Bank of America and Arrowstreet Capital have increased positions.
PHG presents a mixed outlook with solid profitability recovery but technical weakness. The stock offers value at reasonable valuations (P/E 18.84, P/S 1.18) and analyst consensus leans Hold (63.64%). Key risks include cybersecurity threats (Reuters, 2026-08-13) and debt levels, while opportunities lie in healthcare technology expansion and Exor's potential increased stake to 22% (Reuters, 2026-08-11).
U.S. Bancorp (USB) trades at $56.17, down 1.95% on the day, with a bearish technical outlook despite strong fundamentals. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. USB maintains robust profitability with a 27.61% net income margin and attractive valuation metrics including a P/E of 11.21. Recent news highlights dividend increases and positive business momentum in payments and capital markets.
The stock presents a compelling value opportunity with analyst consensus target of $69.94 (24.5% upside), though technical indicators signal near-term caution. Key risks include interest rate sensitivity and regulatory changes, while institutional sentiment remains positive with 51% buy ratings. The upcoming Q3 earnings report will be critical for confirming the positive fundamental trajectory.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →